Compare ARL & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | PRQR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | ARL | PRQR |
|---|---|---|
| Price | $16.10 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 1.6K | ★ 558.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $49,060,000.00 | $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.43 | $1.07 |
| 52 Week High | $17.00 | $3.46 |
| Indicator | ARL | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 58.54 |
| Support Level | $15.26 | $2.15 |
| Resistance Level | $15.98 | $2.42 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 65.71 | 96.46 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.